Skip to main content
OpenTrials
Completed

NCT Number: NCT03897751

A Safety and Effectiveness Study of BL-ABT12 Multi-Purpose Solution for Use by Participants With Soft Contact Lenses

This study is to evaluate the safety and effectiveness of ABT12 Multi-Purpose solution (Test) compared to COMPLETE® Multi-Purpose Solution Easy Rub® Formula ("COMPLETE Multi-Purpose Solution") when used by participants who are habitual contact lens wearers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Bausch Site 1, Birmingham, Alabama, United States

Loading trial locations.

About this study

Eligible participants will be enrolled from 1 of 5 lens groups based on their habitual contact lenses. Participants will be randomized on a 1:1 basis within each group per site to receive either ABT12 Multi-Purpose solution or COMPLETE Multi-Purpose Solution. The 5 lens groups will be comprised of habitual wearers of soft lenses based on the following lens material:

  • Etaficon A, Acuvue2, Vistakon
  • Balafilcon A, PureVision2, Bausch + Lomb
  • Samfilcon A, Ultra, Bausch + Lomb
  • Lotrafilcon B, Optix Aqua, Alcon
  • Senofilcon C, Vita, Vistakon

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is able to read, understand, and provide written informed consent on the Institutional Review Board (IRB) approved Informed Consent Form (ICF) and provide authorization as appropriate local privacy regulations
  • Is a habitual wearer (at least 3 months) of one of the following lens types: 1) Etaficon A, Acuvue2, Vistakon; 2) Balafilcon A, PureVision2, Bausch + Lomb; 3) Samfilcon A, Ultra, Bausch + Lomb; 4) Lotrafilcon B, Optix Aqua, Alcon; 5) Senofilcon C, Vita, Vistakon
  • Vision is correctable through spherocylindrical refraction to 32 letters (0.3 logarithm of the minimum angle of resolution [logMAR]) or better (distance, high contrast) in each eye with soft spherical contact lenses
  • Has clear central corneas and is free of any anterior segment disorders
  • Is a habitual user of a lens care product for cleaning, disinfecting, and storage of lenses
  • Requires lens correction in both eyes
  • Wears the same manufacturer and brand of lens in both eyes
  • Agrees to wear study lenses on a daily wear basis for approximately 3 months
  • Is willing and able to comply with all treatment and follow-up/study procedures

Exclusion criteria

  • Participants who currently use a hydrogen-peroxide cleaning and disinfecting solution
  • Participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation
  • Females of childbearing potential (those who are not surgically sterilized or postmenopausal), if they are currently pregnant, plan to become pregnant during the study, or are breastfeeding
  • Has worn gas permeable (GP) lenses within the last 30 days.
  • Has worn polymethylmethacrylate (PMMA) lenses within the last 3 months
  • Has any systemic disease currently affecting ocular health or which in the Investigator's opinion may have an effect on ocular health during the course of the study
  • Has any ocular disease or is using any ocular medication
  • Is using any systemic or topical medications that will, in the Investigator's opinion, affect ocular physiology or lens performance
  • Currently wears monovision, multifocal, or toric contact lenses
  • Has ocular astigmatism of 1.00 diopter (D) or greater in either eye
  • Vision is not correctable through spherocylindrical refraction to 32 letters (0.3 logMAR) or better (distance, high contrast) in each eye with soft spherical contact lenses
  • Has anisometropia (spherical equivalent) of greater than 2.00D
  • Has any Grade 2 or greater finding during the slit lamp examination
  • Has corneal infiltrates, of any grade
  • Participants with any "Present" finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear
  • Has any scar or neovascularization within the central 6 millimeters (mm) of the cornea. Note that participants with minor peripheral corneal scarring (that does not extend into the central area), that, in the Investigator's judgment, does not interfere with contact lens wear, are eligible for this study
  • Is aphakic
  • Is amblyopic
  • Has had any corneal surgery (for example, refractive surgery)
  • Is allergic to any component in the study care products
  • Is an employee of any of the study investigative sites or a family member of an employee of the investigative site, including family members living outside of the employee's household
  • Is an Ophthalmologist, an Optometrist, an Optician, or an Ophthalmic Assistant/Technician, or currently resides with a person with any of these specialties
  • Is an employee of a manufacturer of contact lenses or contact lens care products (for example, Alcon, Bausch + Lomb, Ciba Vision, CooperVision, Vistakon, or Johnson & Johnson) or currently resides with a person employed by any of these manufacturers

Treatment and study plan

ABT12 Multi-Purpose Solution

Device

Contact lens cleaning and disinfecting solution

COMPLETE Multi-Purpose Solution

Device

Contact lens cleaning and disinfecting solution

Other names: COMPLETE® Multi-Purpose Solution Easy Rub® Formula

Sensitive Eyes® Rewetting Drops

Device

For use as needed during the study.

Primary outcomes

  1. Overall Comfort

    Time frame: Month 3

    Overall comfort will be assessed for each eye on a scale from 0 to 100, with 100 denoting the most favorable response.

  2. Eye Dryness

    Time frame: Month 3

    Dryness will be assessed for each eye on a scale from 0 to 100, with 100 denoting the most favorable response.

  3. Degree Of Lens Deposits

    Time frame: Month 3

    Degree of lens deposits will be assessed for each eye as none, light, medium, or heavy.

  4. Proportion Of Participants With Eyes With Grade >2 Slit Lamp Findings

    Time frame: Day 0 (post-dispensing) through Month 3

    Graded slit lamp findings will be assessed for each eye using Grades 0 through 4. Greater than Grade 2 findings (Absent, Present) will be summarized at the eye level by treatment.

    Grades are 0(none), 1 (Trace), 2 (Mild), 3 (moderate), 4 (severe)

Sponsors and collaborators

Lead sponsor

Bausch & Lomb Incorporated

Industry

Registry information

Official study title

A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Apr 1, 2019
Registry last updated
Mar 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.